Leading a renaissance in kidney disease treatment

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease.

Year Invested: 2016
Location: Cambridge, Mass.
Visit: www.goldfinchbio.com

Recent News

March 13, 2018
Goldfinch Bio Bolsters Leadership Team by Appointing Dr. Peter Mundel as Chief Scientific Officer and Electing Dr. Frank Maddux to Board of Directors

March 6, 2018
Goldfinch Bio to Present at Cowen and Company Healthcare Conference

December 5, 2017
Goldfinch Bio Appoints Anthony Johnson, M.D., President and Chief Executive Officer, and Michael Broxson, Chief Business and Operating Officer

Read More News

Associated Team Members

Philip Reilly, M.D., J.D.
Venture Partner

Neil Exter

Abbie Celniker, Ph.D.

Eric Green, M.D., Ph.D.